Top Industry Leaders in the Tinea Corporis Market
Latest Tinea Corporis Companies Updates:
Lonza Expands API Manufacturing Capacity with Acquisition of Capsugel Dosage Form Solutions: This December 2023 acquisition strengthens Lonza's HPAPI capabilities and expands their geographic reach.
Bolloré acquires Chemours' Advanced Process Technologies (APT) business: This November 2023 deal grants Bolloré access to APT's expertise in HPAPI development and manufacturing, particularly for small molecules.
Pfizer Collaborates with WuXi AppTec for HPAPI Development and Manufacturing: This ongoing partnership leverages WuXi's extensive HPAPI capabilities to support Pfizer's pipeline of potent drugs.
Bristol Myers Squibb Receives FDA Approval for Celdura (Paclitaxel) Injectable Emulsion: This November 2023 approval expands treatment options for cancer patients with a new formulation of a potent HPAPI.
Eli Lilly Announces Positive Phase III Results for Lorlatinib for ALK-positive Non-Small Cell Lung Cancer: This promising development in December 2023 could lead to a new targeted therapy using an HPAPI.
List of Tinea Corporis Key companies in the market:
- Taro Pharmaceuticals., Inc.
- Teva Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Inc
- Breckenridge Pharmaceutical, Inc.
- NorthStar Rx LLC
- Aurobindo Pharma Limited,
- Camber Pharmaceuticals, Inc.
- AvKare, Inc.
- Novartis AG
- Sebela Pharmaceuticals, Inc.,
- Bayer AG
